SGLT2 inhibitors in sepsis and critical illness: a precision-medicine perspective on mechanisms, evidence, and future trial design

Sodium-glucose cotransporter-2 (SGLT2) inhibitors have transformed chronic cardiorenal care, but their role in sepsis and critical illness remains uncertain. This Review evaluates whether the anti-inflammatory, endothelial-stabilizing, metabolic, mitochondrial, and renal effects of SGLT2 inhibition can be translated into clinically meaningful benefit across the sepsis continuum. The mechanistic rationale is strong because several proposed drug effects map closely to recognized sepsis pathways, including endothelial barrier failure, immunometabolic dysregulation, mitochondrial dysfunction, regulated cell death, septic cardiomyopathy, and sepsis-associated acute kidney injury. However, clinical evidence remains limited and heterogeneous. Observational prior-use studies suggest favorable associations but are vulnerable to confounding, while the first large randomized trial in acute critical illness, DEFENDER, found no overall clinical benefit of dapagliflozin in a broad ICU population. Exploratory analyses have nevertheless generated signals related to diuresis, fluid balance, and loop-diuretic usage, supporting a more targeted research strategy. Current evidence does not support routine initiation of SGLT2 inhibitors during acute sepsis or septic shock outside clinical trials, particularly during active shock, fasting, unstable renal perfusion, or metabolic stress. Future studies should avoid all-comer sepsis designs and instead focus on phenotype-enriched populations, safer timing windows such as stabilization or de-resuscitation, and post-ICU cardiorenal recovery. Mechanism-aligned endpoints, structured safety monitoring, biomarker-informed enrichment, and adaptive translational trial designs will be essential to determine whether SGLT2 inhibition can move from biologic plausibility to clinical utility in sepsis and critical illness.

Authors

Institutions

Publication Details

Journal
Frontiers in Medicine
Published
2026-11-12
DOI
https://doi.org/10.3389/fmed.2026.1891235
Primary Topic
Sepsis Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

SGLT2 inhibitors in sepsis and critical illness: a precision-medicine perspective on mechanisms, evidence, and future trial design

Jun Qiu, HongYe Wang
Frontiers in Medicine
Sepsis Diagnosis and Treatment
article

SGLT2 inhibitors in sepsis and critical illness: a precision-medicine perspective on mechanisms, evidence, and future trial design

Jun Qiu, HongYe Wang
article en

Abstract

Sodium-glucose cotransporter-2 (SGLT2) inhibitors have transformed chronic cardiorenal care, but their role in sepsis and critical illness remains uncertain. This Review evaluates whether the anti-inflammatory, endothelial-stabilizing, metabolic, mitochondrial, and renal effects of SGLT2 inhibition can be translated into clinically meaningful benefit across the sepsis continuum. The mechanistic rationale is strong because several proposed drug effects map closely to recognized sepsis pathways, including endothelial barrier failure, immunometabolic dysregulation, mitochondrial dysfunction, regulated cell death, septic cardiomyopathy, and sepsis-associated acute kidney injury. However, clinical evidence remains limited and heterogeneous. Observational prior-use studies suggest favorable associations but are vulnerable to confounding, while the first large randomized trial in acute critical illness, DEFENDER, found no overall clinical benefit of dapagliflozin in a broad ICU population. Exploratory analyses have nevertheless generated signals related to diuresis, fluid balance, and loop-diuretic usage, supporting a more targeted research strategy. Current evidence does not support routine initiation of SGLT2 inhibitors during acute sepsis or septic shock outside clinical trials, particularly during active shock, fasting, unstable renal perfusion, or metabolic stress. Future studies should avoid all-comer sepsis designs and instead focus on phenotype-enriched populations, safer timing windows such as stabilization or de-resuscitation, and post-ICU cardiorenal recovery. Mechanism-aligned endpoints, structured safety monitoring, biomarker-informed enrichment, and adaptive translational trial designs will be essential to determine whether SGLT2 inhibition can move from biologic plausibility to clinical utility in sepsis and critical illness.

Frontiers in MedicineVol. 13
Second People’s Hospital of Yibin (CN)
Good health and well-being
Sepsis Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon